PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRepaglinide
Prandin, Novonorm(repaglinide)
Enyglid, NovoNorm, Prandimet, Prandin, Repaglinide (repaglinide) is a small molecule pharmaceutical. Repaglinide was first approved as Prandin on 1997-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against ATP-binding cassette sub-family C member 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Repaglinide (discontinued: Prandin, Repaglinide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metformin hydrochloride
+
Repaglinide
Tradename
Company
Number
Date
Products
PRANDIMETNovo NordiskN-022386 DISCN2008-06-23
2 products, RLD
Hide discontinued
Repaglinide
Tradename
Company
Number
Date
Products
PRANDINGemini LaboratoriesN-020741 DISCN1997-12-22
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
prandinNew Drug Application2017-12-28
repaglinideANDA2025-09-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD14: Metformin and repaglinide
— A10BX: Other blood glucose lowering drugs, excl. insulins in atc
— A10BX02: Repaglinide
HCPCS
No data
Clinical
Clinical Trials
86 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11426211244
Diabetes mellitusD003920EFO_0000400E08-E133—6141033
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FibrosisD005355————2—24
Cystic fibrosisD003550EFO_0000390E84——2—24
HypertensionD006973EFO_0000537I10—12——2
Cardiovascular diseasesD002318EFO_0000319I98——1—12
Chronic renal insufficiencyD051436—N18111——2
Kidney diseasesD007674EFO_0003086N08111——2
HypercholesterolemiaD006937————1——1
Coronary diseaseD003327————1——1
AtherosclerosisD050197EFO_0003914I25.1——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoglycemiaD007003—E16.2—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———17————17
Drug interactionsD004347——4———15
ObesityD009765EFO_0001073E66.92———13
NeoplasmsD009369—C802————2
Mitochondrial diseasesD028361EFO_0000591—1————1
StrokeD020521EFO_0000712I63.91————1
HypersensitivityD006967EFO_0003785T78.401————1
Parkinson diseaseD010300EFO_0002508G201————1
RecurrenceD012008——1————1
Ovarian neoplasmsD010051EFO_0003893C561————1
Show 15 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes complicationsD048909——————11
Morbid obesityD009767EFO_0001074—————11
Bariatric surgeryD050110——————11
PancreatitisD010195EFO_0000278K85————11
Pancreatic neoplasmsD010190EFO_0003860C25————11
Heart failureD006333EFO_0003144I50————11
Prediabetic stateD011236EFO_1001121R73.03————11
Glucose intoleranceD018149HP_0000833R73.03————11
Exocrine pancreatic insufficiencyD010188—K86.81————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRepaglinide
INNrepaglinide
Description
Repaglinide is a member of piperidines.
Classification
Small molecule
Drug classantidiabetic, sodium glucose co-transporter 2 (SGLT2) inhibitors, not phlorozin derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O
Identifiers
PDB—
CAS-ID135062-02-1
RxCUI—
ChEMBL IDCHEMBL1272
ChEBI ID8805
PubChem CID65981
DrugBankDB00912
UNII ID668Z8C33LU (ChemIDplus, GSRS)
Target
Agency Approved
ABCC8
ABCC8
Organism
Homo sapiens
Gene name
ABCC8
Gene synonyms
HRINS, SUR, SUR1
NCBI Gene ID
6833
Protein name
ATP-binding cassette sub-family C member 8
Protein synonyms
ATP-binding cassette transporter sub-family C member 8, ATP-binding cassette, sub-family C (CFTR/MRP), member 8, sulfonylurea receptor (hyperinsulinemia), Sulfonylurea receptor 1
Uniprot ID
Q16583
Mouse ortholog
Abcc8 (20927)
ATP-binding cassette sub-family C member 8 (B2RUS7)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Repaglinide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,022 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,963 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use